

**Table 7. Antiretroviral Components Not Recommended as Initial Therapy**  
(Updated December 1, 2009)

ARV Drugs or Components (in alphabetical order)	Reasons for <b>NOT</b> recommending as initial therapy
ABC/3TC/ZDV (coformulated) as triple-NRTI combination regimen ( <b>BI</b> )	<ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> </ul>
ABC + 3TC + ZDV + TDF as quadruple-NRTI combination ( <b>BI</b> )	<ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> </ul>
ABC + ddI ( <b>BIII</b> )	<ul style="list-style-type: none"> <li>• Insufficient data in ART-naïve patients</li> </ul>
ABC + TDF ( <b>BIII</b> )	<ul style="list-style-type: none"> <li>• Insufficient data in ART-naïve patients</li> </ul>
DRV (unboosted)	<ul style="list-style-type: none"> <li>• Use without RTV has not been studied</li> </ul>
DLV ( <b>BII</b> )	<ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> <li>• Inconvenient (three times daily) dosing</li> </ul>
ddI + TDF ( <b>BII</b> )	<ul style="list-style-type: none"> <li>• High rate of early virologic failure</li> <li>• Rapid selection of resistance mutations</li> <li>• Potential for immunologic nonresponse/CD4 T-cell decline</li> <li>• Increased ddI drug exposure and toxicities</li> </ul>
T-20 ( <b>BIII</b> )	<ul style="list-style-type: none"> <li>• No clinical trial experience in ART-naïve patients</li> <li>• Requires twice-daily subcutaneous injections</li> </ul>
ETR ( <b>BIII</b> )	<ul style="list-style-type: none"> <li>• Insufficient data in ART-naïve patients</li> </ul>
IDV (unboosted) ( <b>BIII</b> )	<ul style="list-style-type: none"> <li>• Inconvenient dosing (three times daily with meal restrictions)</li> <li>• Fluid requirement</li> </ul>
IDV (RTV-boosted) ( <b>BIII</b> )	<ul style="list-style-type: none"> <li>• High incidence of nephrolithiasis</li> </ul>
NFV ( <b>BI</b> )	<ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> <li>• High incidence of diarrhea</li> </ul>
RTV as sole PI ( <b>BIII</b> )	<ul style="list-style-type: none"> <li>• High pill burden</li> <li>• Gastrointestinal intolerance</li> </ul>
SQV (unboosted) ( <b>BI</b> )	<ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> </ul>
d4T + 3TC ( <b>BI</b> )	<ul style="list-style-type: none"> <li>• Significant toxicities including lipoatrophy; peripheral neuropathy; and hyperlactatemia, including symptomatic and life-threatening lactic acidosis, hepatic steatosis, and pancreatitis</li> </ul>
TPV (ritonavir-boosted) ( <b>BI</b> )	<ul style="list-style-type: none"> <li>• Inferior virologic efficacy</li> </ul>

**Acronyms:** 3TC = lamivudine, ABC = abacavir, ARV = antiretroviral, d4T = stavudine, ddI = didanosine, DLV = delavirdine, DRV = darunavir, ETR = etravirine; IDV = indinavir, IDV/r = ritonavir-boosted indinavir, NFV = nelfinavir, NRTI = nucleoside reverse transcriptase inhibitor, RTV = ritonavir, SQV = saquinavir, T-20 = enfuvirtide, TDF = tenofovir, TPV = tipranavir, ZDV = zidovudine